 <p>LEGACY HEALTH</p>	<p><b>Legacy Day Treatment Unit Provider's Orders</b></p> <p>Adult Ambulatory Infusion Order ROMOSOZUMAB-AQQG (EVENTITY) INJECTION</p>	<p><b>Patient Name:</b> _____</p> <p><b>Date of Birth:</b> _____</p> <p><b>Med. Rec. No (TVC MRN Only):</b> _____</p>
<p>ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE</p>		

**Anticipated Start Date:** \_\_\_\_\_ **Patient to follow up with provider on date:** \_\_\_\_\_

**\*\*\*This plan will expire after 365 days, unless otherwise specified below\*\*\***

**Orders expire:** \_\_\_\_\_

**Weight:** \_\_\_\_\_ kg    **Height:** \_\_\_\_\_ cm

**Allergies:** \_\_\_\_\_

**Diagnosis:** \_\_\_\_\_

**Diagnosis Code:** \_\_\_\_\_ (please include primary and secondary diagnosis codes)

**GUIDELINES FOR PRESCRIBING:**


1. Send **FACE SHEET and H&P or most recent chart note.**
2. Romosozumab may increase the risk of MI, stroke, and cardiovascular death. It should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors.
3. Duration of therapy is limited to 12 monthly doses.
4. Confirm patient has had recent oral/dental evaluation if indicated prior to initiating therapy.
5. Hypocalcemia must be corrected prior to initiation of therapy. All patients should be prescribed daily calcium and Vitamin D supplementation.
6. Risk versus benefit regarding osteonecrosis of the jaw and hip fracture must be discussed prior to treatment.
7. A complete metabolic panel is recommended, and a calcium level must be obtained within 30 days prior to starting treatment.
8. **Must complete and check the following box:**
  - Provider confirms that the patient has had a recent oral or dental evaluation and/or has no contraindications to therapy related to dental issues prior to initiating therapy

**LABS TO BE DRAWN (orders must be placed in TVC Epic by ordering provider if TVC provider):**

- Complete Metabolic Panel, Routine, ONCE, every visit

**NURSING ORDERS (TREATMENT PARAMETERS):**

1. TREATMENT PARAMETER #1 – Pharmacist to calculate Corrected Calcium. Hold and contact provider for Corrected Calcium less than 8.4 mg/dL.
2. Assess for new or unusual thigh, hip, groin, or jaw pain. Inform provider if positive findings or if patient is anticipating invasive dental work.
3. Please remind patient to take at least 500 mg elemental calcium twice daily and 400 IU Vitamin D daily.
4. RN to assess for previous myocardial infarction (MI) or stroke at every visit. Hold and contact provider if patient had a MI or stroke. Romosozumab-aqqg may increase the risk of MI, stroke, and cardiovascular death. If a patient experiences a MI or stroke during therapy, romosozumab-aqqg should be discontinued.
5. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, dec clotting (alteplase), and/or dressing changes.

 <p><b>LEGACY HEALTH</b></p>	<p><b>Legacy Day Treatment Unit Provider's Orders</b></p> <p>Adult Ambulatory Infusion Order ROMOSOZUMAB-AQQG (EVENTITY) INJECTION</p>	<p><b>Patient Name:</b></p> <p><b>Date of Birth:</b></p> <p><b>Med. Rec. No (TVC MRN Only):</b></p>
<p>ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE</p>		

**MEDICATIONS:**

- Romosozumab-aqqg (EVENTITY) 210 mg injection, subcutaneous, ONCE, every 4 weeks for 12 doses

Allow syringes to sit at room temperature for at least 30 minutes before use. Inject two 105 mg/1.17 mL syringes for a total dose of 210 mg. Administer into the thigh, abdomen (except for a 2 inch area around the navel), or outer area of upper arm. Rotate injection sites.

**HYPERSENSITIVITY MEDICATIONS:**

1. NURSING COMMUNICATION - If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Refer to LH policy 906.6606 Initiation of Emergency Measures for Adult Oncology, Radiation Oncology and Infusion Clinic Patients
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. Avoid use of steroids unless directed by provider. Steroids may compromise effectiveness of drug.
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
6. albuterol (PROVENTIL HFA) inhaler, 4 puff, inhalation, EVERY 4 HOURS PRN, wheezing
7. 0.9% NaCl, 500 mL, intravenous, CONTINUOUS PRN over 2.5 hours, for hypersensitivity or infusion reaction

Please check the appropriate box for the patient's preferred clinic location:

**Legacy Day Treatment Unit –  
The Vancouver Clinic Building**  
*A department of Salmon Creek Medical Center*  
700 NE 87<sup>th</sup> Avenue, Suite 360  
Vancouver, WA 98664  
Phone number: 360-896-7070  
Fax number: 360-487-5773

**Legacy Emanuel Day Treatment Unit**  
*A department of Emanuel Medical Center*  
501 N Graham Street, Suite 540  
Portland, OR 97227  
Phone number: 503-413-4608  
Fax number: 503-413-4887

**Legacy Salmon Creek Day Treatment Unit**  
Legacy Salmon Creek Medical Center  
2121 NE 139<sup>th</sup> Street, Suite 110  
Vancouver, WA 98686  
Phone number: 360-487-1750  
Fax number: 360-487-5773

**Legacy STEPS Clinic**  
*A department of Silverton Medical Center*  
Legacy Woodburn Health Center  
1475 Mt Hood Ave  
Woodburn, OR 97071  
Phone number: 503-982-1280  
Fax number: 503-225-8723

**Provider signature:** \_\_\_\_\_ **Date/Time:** \_\_\_\_\_

**Printed Name:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_

**Organization/Department:** \_\_\_\_\_